Aldeyra Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Aldeyra Therapeutics Director Nancy Miller-Rich acquired stock options for 73,318 shares of common stock.
NASDAQ
Richard Douglas, a Director at Aldeyra Therapeutics, acquired stock options for 70,000 shares, with additional options for 19,909 and 2,323 shares, all exercisable at $1.72.
NASDAQ
Aldeyra Therapeutics Director Gary M. Phillips acquired stock options for 70,000 shares of common stock.
NASDAQ
Aldeyra Therapeutics Director William D. Clark acquired stock options for 72,323 shares of common stock.
NASDAQ
Aldeyra Therapeutics Director Neal Walker acquired stock options for 73,318 shares, with exercise prices of $1.72, as detailed in a Form 4 filing.
NASDAQ
Aldeyra Therapeutics Director Ben Bronstein acquired stock options for 70,000 shares of common stock.
NASDAQ
Aldeyra Therapeutics Director Darlene M. Deptula-Hicks acquired stock options for 84,557 shares and 9,756 shares, with exercise prices of $1.72, as detailed in a Form 4 filing.
NASDAQ
Aldeyra Therapeutics CEO Todd C. Brady acquired 250,000 shares of common stock in an open market transaction.
NASDAQ
Aldeyra Therapeutics' President and CEO, Todd C. Brady, received substantial stock options and bonus units, aligning executive incentives with long-term company performance.
NASDAQ
Aldeyra Therapeutics Director Richard Douglas acquired 70,000 shares of common stock at $1.40 per share.
NASDAQ
Aldeyra Therapeutics' Principal Financial Officer, Michael Alfieri, purchased 5,000 shares of common stock at $1.42 per share.
NASDAQ
Aldeyra Therapeutics' Principal Financial Officer, Michael Alfieri, purchased 2,500 shares of common stock for $13,250.
NASDAQ
Aldeyra Therapeutics' Chief Development Officer, Stephen Machatha, sold 22,073 shares of common stock to cover tax withholding obligations related to restricted stock unit awards.
NASDAQ
Aldeyra Therapeutics, Inc. Director Neal Walker was granted a total of 65,141 stock options with an exercise price of $2.685, vesting over one year subject to continued service.
NASDAQ
Aldeyra Therapeutics, Inc. Director Nancy Miller-Rich was granted 65,141 stock options with an exercise price of $2.685, vesting over one year subject to continued service.
NASDAQ
Aldeyra Therapeutics, Inc. Director Ben Bronstein was granted 70,207 stock options with an exercise price of $2.685 per share, vesting over one year subject to continued service.
NASDAQ
Aldeyra Therapeutics, Inc. director Martin Joseph Joyce was granted 71,655 stock options with an exercise price of $2.685, vesting over one year subject to continued service.
NASDAQ
Aldeyra Therapeutics, Inc. Director Richard Douglas was granted 78,893 stock options with an exercise price of $2.685, vesting over one year, as compensation for his board service.
NASDAQ
Aldeyra Therapeutics, Inc. Director Gary M. Phillips was granted 71,172 stock options with an exercise price of $2.685, vesting over one year subject to continued service.
NASDAQ
Director William D. Clark acquired stock options in Aldeyra Therapeutics, Inc. exercisable over three years.
NASDAQ
Perceptive Advisors LLC, along with related entities, sold 3,400,000 shares of Aldeyra Therapeutics (ALDX) at an average price of $1.42 on April 3, 2025.
NASDAQ
Aldeyra Therapeutics CEO Todd C. Brady reports the acquisition of stock options in the company.
NASDAQ
Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics, reports the acquisition of stock options.
NASDAQ
Nancy Miller-Rich, a director of Aldeyra Therapeutics, reported transactions involving the company's common stock due to trades executed by an investment advisor.
NASDAQ
Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics, sold 16,041 shares of common stock to cover tax withholding obligations.
NASDAQ
Bruce Greenberg, Interim CFO of Aldeyra Therapeutics, sold shares to cover tax withholding obligations related to the settlement of restricted stock units.
NASDAQ
Director Richard Douglas acquired stock options in Aldeyra Therapeutics, Inc. on June 4, 2024.
NASDAQ
Martin Joyce, a director at Aldeyra Therapeutics, reports the acquisition of stock options.
NASDAQ
Director Neal Walker acquired stock options in Aldeyra Therapeutics, according to a Form 4 filing.
NASDAQ
Nancy Miller-Rich, a director at Aldeyra Therapeutics, acquired stock options on June 4, 2024.